睿知中国医院研究地图
候选清单

正在招募鼻咽癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验。牵头方不是本站收录的医院;本站收录的 14 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 14

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院肿瘤医院深圳医院Cancer Hospital CAMS – Shenzhen深圳医院页面
  2. 研究中心东莞市人民医院Dongguan People's Hospital东莞医院页面
  3. 研究中心赣南医科大学第一附属医院First Affiliated Hospital of Gannan Medical University赣州医院页面
  4. 研究中心广东药科大学附属第一医院First Affiliated Hospital of Guangdong Pharmaceutical University广州医院页面
  5. 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
  6. 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
  7. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  8. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  9. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  10. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  11. 研究中心四川大学华西医院West China Hospital成都医院页面
  12. 研究中心中南大学湘雅医院Xiangya Hospital长沙医院页面
  13. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
  14. 研究中心中山市人民医院Zhongshan City People's Hospital中山医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06839066,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed recurrent/metastatic nasopharyngeal carcinoma;

    入选标准第 3 条

  3. History of other malignancies within 2 years prior to randomization (except radically treated early-stage malignancies).

    排除标准第 3 条

  4. Recurrent/metastatic nasopharyngeal carcinoma patients who have failed or are intolerant to at least two prior lines of chemotherapy (including at least one platinum-based regimen) and PD-1/PD-L1 inhibitor therapy. Intolerance is defined as experiencing CTCAE ≥ grade 3 adverse events;

    入选标准第 4 条

    At least 4 weeks (or 5 half-lives, whichever is shorter) since last major surgery, medical device treatment, radiotherapy (except palliative bone radiotherapy), cytotoxic chemotherapy, immunotherapy, or biological therapy; ≥2 weeks since last hormonal therapy or small molecule targeted therapy; ≥1 week since last traditional Chinese medicine treatment with anti-tumor indications or minor surgery; with treatment-related adverse events recovered to CTCAE v5.0 ≤ grade 1 (except grade 2 peripheral neuropathy and alopecia);

    入选标准第 7 条

    Previous ≥Grade 3 immune-related adverse events during immunotherapy.

    排除标准第 4 条

  5. ECOG performance status 0-1 within 1 week before randomization;

    入选标准第 8 条

  6. At least one measurable lesion per RECIST v1.1 within 4 weeks before randomization;

    入选标准第 5 条

  7. Immunodeficiency disorders (HIV-positive or congenital/acquired immune deficiencies).

    排除标准第 17 条

    Active HBV/HCV infection or co-infection:

    排除标准第 18 条

  8. Fertile participants must use ≥1 highly effective contraceptive method during the trial and for ≥6 months after last dose; females of childbearing potential must have negative pregnancy test within 7 days before enrollment.

    入选标准第 11 条

    Pregnant/lactating women.

    排除标准第 19 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06839066,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Fully understand the study content, procedures, and potential adverse reactions before the trial, sign the informed consent form (ICF), voluntarily participate in the trial, and be able to complete the study per the protocol requirements;
  2. Age ≥ 18 years at the time of signing the ICF, regardless of gender;
  3. Histologically or cytologically confirmed recurrent/metastatic nasopharyngeal carcinoma;
  4. Recurrent/metastatic nasopharyngeal carcinoma patients who have failed or are intolerant to at least two prior lines of chemotherapy (including at least one platinum-based regimen) and PD-1/PD-L1 inhibitor therapy. Intolerance is defined as experiencing CTCAE ≥ grade 3 adverse events;
  5. At least one measurable lesion per RECIST v1.1 within 4 weeks before randomization;
  6. Willing to provide archived (preferably within 2 years) or fresh tumor tissue specimens for the detection of PD-L1 expression.
  7. At least 4 weeks (or 5 half-lives, whichever is shorter) since last major surgery, medical device treatment, radiotherapy (except palliative bone radiotherapy), cytotoxic chemotherapy, immunotherapy, or biological therapy; ≥2 weeks since last hormonal therapy or small molecule targeted therapy; ≥1 week since last traditional Chinese medicine treatment with anti-tumor indications or minor surgery; with treatment-related adverse events recovered to CTCAE v5.0 ≤ grade 1 (except grade 2 peripheral neuropathy and alopecia);
  8. ECOG performance status 0-1 within 1 week before randomization;
  9. Expected survival ≥ 3 months;
  10. Adequate organ function within 1 week before randomization (no blood transfusion or colony-stimulating factors within 14 days prior to first dose)
  11. Fertile participants must use ≥1 highly effective contraceptive method during the trial and for ≥6 months after last dose; females of childbearing potential must have negative pregnancy test within 7 days before enrollment.

排除标准:Exclusion Criteria:

  1. Recurrent nasopharyngeal carcinoma candidates eligible for curative local therapy (surgery or radiotherapy).
  2. Imaging showing tumor invasion/encasement of major thoracic/cervical/pharyngeal blood vessels (may be exempted if investigators confirm no impact on trial participation).
  3. History of other malignancies within 2 years prior to randomization (except radically treated early-stage malignancies).
  4. Previous ≥Grade 3 immune-related adverse events during immunotherapy.
  5. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  6. Symptomatic/untreated/progressing CNS or leptomeningeal metastases.
  7. History of ≥Grade 3 radiation pneumonitis; steroid-requiring (non-infectious) interstitial lung disease (ILD), current ILD, or ILD unexcludable by imaging; or severe respiratory impairment from pulmonary disease.
  8. Poorly controlled cardiovascular/cerebrovascular conditions including.
  9. Candidates for organ/marrow transplantation or previous transplant recipients.
  10. Active systemic infections requiring IV antibiotics within 2 weeks pre-randomization.
  11. Use of strong CYP2D6/CYP3A inhibitors/inducers within 2 weeks pre-randomization.
  12. Systemic corticosteroid use (>10mg prednisone/day equivalent) or immunosuppressants within 2 weeks pre-randomization. Exceptions: Topical/ocular/intra-articular/nasal/inhaled steroids; short-term prophylactic use for contrast agents.
  13. Active/suspected autoimmune diseases. Exceptions: Hypothyroid patients on thyroid replacement; controlled type 1 diabetes with insulin.
  14. Live/attenuated vaccines within 4 weeks pre-randomization (inactivated influenza vaccines permitted).
  15. History of severe hypersensitivity to biologics/monoclonal antibodies or trial drug components.
  16. Active tuberculosis.
  17. Immunodeficiency disorders (HIV-positive or congenital/acquired immune deficiencies).
  18. Active HBV/HCV infection or co-infection:
  19. Pregnant/lactating women.
  20. Investigators' judgment of clinical/lab abnormalities or other factors making participation inappropriate.

引自 ClinicalTrials.gov, NCT06839066, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06839066,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06839066